Search results
Results from the WOW.Com Content Network
FDA inspectors identified the issues at Neuralink's animal testing facilities in California in June 2023, several weeks after the agency had given the company the green light for a small study of ...
Neuralink did not respond to questions about the FDA visit. The FDA has not issued its designation indicating the severity of problems found in the inspection, according to the agency's database.
The agency also said it routinely carries out inspections after a human trial is approved. When it inspected Neuralink, the FDA said it did not find violations that would undermine the safety of ...
The investigation has come at a time of growing employee dissent about Neuralink’s animal testing, including complaints that pressure from CEO Musk to accelerate development has resulted in ...
Maropitant (INN; [3] brand name: Cerenia, used as maropitant citrate , is a neurokinin-1 (NK 1) receptor antagonist developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007, for use in dogs [4] [5] and in 2012, for cats. [6]
The FDA's breakthrough tag is given to certain medical devices that provide treatment or diagnosis of life-threatening conditions. The experimental device, known as Blindsight, "will enable even ...
On January 5, 2007, the U.S. Food and Drug Administration (FDA) approved Slentrol, the first time the FDA has approved a drug for obese dogs. [ 3 ] [ 4 ] However, concerns have since been raised, since 2010, about adverse effects [ 5 ] that might more strongly affect particular breeds .
Most of the other contraindications are avoiding cases where a potential side effect exacerbates a pre-existing condition: for example, because oclacitinib can cause lumps or tumors, it should not be used in dogs with cancer or a history of it; [15] because it is an immune system suppressant, it should not be used in dogs with serious infections.